ipilimumab,nivolumab,durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['nsclc', 'sclc']
efs looks strong and provides further strong evidence of benefit of neoadjuvant chemo/immunotherapy approach. should be standard of care for clinical stage ii/iii patients with resectable nsclc. #aacr23 
Thoracic surgeon expecting excellence. Cancer researcher. Patient advocate. #LungCancer #lcsm @lung_fund